bioAffinity Technologies highlights a new clinical framework for CyPath Lung

bioAffinity Technologies (Nasdaq: BIAF) is highlighting a new clinical framework that explains where CyPath® Lung may fit in the evaluation of pulmonary nodules and ongoing lung cancer surveillance. The company is presenting the test as a noninvasive option that may help clinicians better assess risk in patients who need further follow-up.

• bioAffinity Technologies published a new clinical framework for CyPath® Lung.
• The paper focuses on pulmonary nodule risk stratification and early lung cancer detection.
• The framework is aimed at primary care, pulmonology, and oncology practices.
• The company says CyPath® Lung should be used alongside, not instead of, existing diagnostic tools.
• Investors may view the update as a commercial positioning move for a growing lung-cancer diagnostics market.

How the framework is meant to be used

The paper, authored by Chief Medical Officer Gordon H. Downie, MD, PhD, examines how lung screening is uncovering more incidental nodules and increasing the need for better risk assessment. It argues that no single diagnostic tool should be used in isolation and instead proposes specialty-specific pathways for different care settings. Those pathways are designed for primary care practices, interventional pulmonology programs, and oncology clinics that follow cancer survivors.

Why the timing matters

The company says the need for better nodule management is growing as screening expands and AI helps identify more incidental findings. That gives CyPath® Lung a larger potential role in care pathways where doctors need help deciding who should be monitored, biopsied, or sent for additional testing. For a diagnostics company, that kind of clinical framework can help support adoption by making the product easier for physicians to understand and use.

Investor takeaway

For investors, this looks like both a clinical and commercial marketing step for bioAffinity Technologies. If the framework helps drive more physician awareness and ordering volume, it could support CyPath® Lung’s growth story in lung cancer diagnostics. The key question is whether the paper translates into broader clinical use and stronger revenue momentum over time.